02/10/2026
Why Reuteri? Meaningful adjunctive increase in H pylori eradication rate, attenuation of symptoms and treatment side effects when L. reuteri was given as an adjunct treatment.
This 2023 RCT involved ninety treatment-naïve H. pylori positive patients who received standard triple therapy for 2 weeks before receiving either 4 billion cfu L. reuteri or placebo for 4 weeks.
The H. pylori eradication rate was significantly higher in the probiotic group than in the placebo group, with a 22.2% improvement in the intention-to-treat analysis (91.1% vs. 68.9%; p = 0.007) and 24.3% improvement in the per-protocol analysis (93.2% vs. 68.9%; p = 0.007).
Ismail NI, Nawawi KNM, Hsin DCC, Hao KW, Mahmood NRKN, Chearn GLC, Wong Z, Tamil AM, Joseph H, Raja Ali RA. Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double-blind, placebo-controlled trial. Helicobacter. 2023
Peng Y, Ma Y, Luo Z, Jiang Y, Xu Z, Yu R. Lactobacillus reuteri in digestive system diseases: focus on clinical trials and mechanisms. Front Cell Infect Microbiol. 2023 Aug 18;13:1254198.
Peng Y, Ma Y, Luo Z, Jiang Y, Xu Z, Yu R. Lactobacillus reuteri in digestive system diseases: focus on clinical trials and mechanisms. Front Cell Infect Microbiol. 2023 Aug 18;13:1254198.